7 unknown, 4 completed, 4 recruiting, 1 not yet recruiting. 16 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Unknown 7, Completed 4, Recruiting 4, Not yet recruiting 1 |
| Phase 2 | 9 | Unknown 5, Recruiting 3, Not yet recruiting 1 |
Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis SHR-A1811, Bevacizumab, Pyrotinib - Breast Cancer Metastatic, Breast Cancer Brain Metastases | Phase 1 / Phase 2 | Recruiting | Fudan University | 74 | 2025-01-08 | 2025-02-06 |
| The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study Pyrotinib low dose group, Pyrotinib normal dose group - Breast Cancer | Phase 1 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2024-11-01 | 2025-01-13 |
| A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies - HER2-expressing Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 364 | 2023-08-11 | 2024-08-05 |
| Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects pyrotinib tablet, Montmorillonite Power, Loperamide - HER2-positive Recurrent / Metastatic Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 36 | 2022-03-08 | 2022-12-23 |
| Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer Docetaxel, trastuzumab, Pyrotinib - Metastatic Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 97 | 2020-05-28 | 2023-09-18 |
| A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer Pyrotinib in combination with capecitabine - HER-2 Positive Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Qingdao Zhixin Health Technology Co., Ltd. | 34 | 2020-01-10 | 2020-01-14 |
| Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases Pyrotinib Plus Capecitabine combined with brain radiotherapy - Breast Cancer, Brain Metastases | Phase 1 / Phase 2 | Unknown | Fudan University | 39 | 2020-01-02 | 2023-01-18 |
| Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects pyrotinib tablet, Itraconazole capsule - Healthy Subjects | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2019-09-18 | 2020-07-21 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 59 | 2019-05-12 | 2023-03-07 |
| FUSCC Refractory TNBC Umbrella (FUTURE) Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel - Triple-negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 140 | 2018-10-18 | 2022-08-10 |
| Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Pyrotinib - Breast Cancer, Gastric Cancer | Phase 1 | Unknown | Hengrui Therapeutics, Inc. | 50 | 2015-06-01 | 2021-02-01 |
| A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab pyrotinib, Lapatinib, capecitabine - HER2 Positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 128 | 2015-05-01 | 2018-07-09 |
| Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer Pyrotinib/Pyrotinib with Docetaxel - HER2 Positive Gastric Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 28 | 2014-09-01 | 2015-03-04 |
| Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer Pyrotinib - Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 40 | 2013-01-01 | 2018-07-09 |
Breast Neoplasms (8) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (7) · Fudan University (4) · Hengrui Therapeutics, Inc. (1) · Qingdao Zhixin Health Technology Co., Ltd. (1) · RemeGen Co., Ltd. (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (15) · United States (1)
Biyun Wang, Chief physician (1) · Hongxia Wang, Chief physician (1) · Junsheng Wang, MD (1) · Xiaoli Yu, MD PhD (1) · Yongmei Yin, Ph.D (1) · Zhimin U Shao, Professor (1)
PMID 39024777, PMID 27602761, PMID 32719455, PMID 32898333, PMID 35105939, PMID 35321427, PMID 36135045, PMID 36803645, PMID 37081722, PMID 38175627, PMID 38290515, PMID 40433999, PMID 40743286